Leveraging Bioanalysis to Accelerate Drug Development Programs: Challenges and Considerations

From drug discovery, through to preclinical and clinical studies, understanding drug exposure and behaviour are imperative to dose selection, and accelerating drugs to clinic and commercialization. Bioanalysis is an integral part of the drug development process, particularly in early development where it is used to support preclinical and FIH studies to determine metabolic fate and pharmacokinetics of the drug.